As expected, miR-34a expression was not induced in the treated MDA-231T breast cancer cells, which have R280K p53 mutation, that led to an p53 transcriptional activity measured as 0,8%, making these cells unresponsive to doxorubicine treatment [33]. Here, TP53 is linked to breast cancer.